Collaborations Pharmaceuticals, INC.
UEI EFJCLL37KKH3 · NC · SAM.gov record ↗
$2.0M
FY2025 obligations
1
Contract awards
Sep 28, 2025
First action
Jun 23, 2026
Latest action
Obligations by agency
- Department Of Health And Human Services$2.0M
Obligations by NAICS
Monthly obligations
Sep 25
Jun 26
Contracts ending within 18 months (recompete watch)
- 75N93025C00039 ↗$2.0M
IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U
- Ends
- Dec 28, 2026
- Started
- Sep 28, 2025
- Agency
- National Institutes Of Health
- NAICS
- 541714
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N93025C00039 ↗ | IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U | National Institutes Of Health | 541714 | $2.0M | Sep 28, 2025 | Dec 28, 2026 |
Largest awards
- 75N93025C00039 ↗$2.0M
IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U
- Ends
- Dec 28, 2026
- Started
- Sep 28, 2025
- Agency
- National Institutes Of Health
- NAICS
- 541714
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N93025C00039 ↗ | IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U | National Institutes Of Health | 541714 | $2.0M | Sep 28, 2025 | Dec 28, 2026 |